Publications – AlphaCog

Thomas Prevot
January 16, 2021
No Comments

New Research Article shows Beneficial Effects of a New Drug in Transgenic Mouse Model with Cognitive Dysfunctions and Anxiety Phenotype

New Research Article shows Beneficial Effects of a New Drug in Transgenic Mouse Model with Cognitive Dysfunctions and Anxiety Phenotype http://www.alphacog.ca/wp-content/uploads/2021/01/Capture-wWebsite.jpg 613 472 Thomas Prevot Thomas Prevot http://1.gravatar.com/avatar/441964589afd9a17fb378ee0cd8d1fed?s=96&d=mm&r=g January 16, 2021 January 16, 2021

The paper was published by Fee et al. in the International Journal of Neuropsychopharmacology. Patients suffering from mood and anxiety disorders often exhibit a deficit in brain inhibition. This deficit…

November 5, 2020

A new molecule shows efficacy at reversing brain atrophy observed during aging

A new molecule shows efficacy at reversing brain atrophy observed during aging http://www.alphacog.ca/wp-content/uploads/2019/01/Lightspring_Brain_Medication.jpg 639 450 Thomas Prevot Thomas Prevot http://1.gravatar.com/avatar/441964589afd9a17fb378ee0cd8d1fed?s=96&d=mm&r=g November 5, 2020 January 4, 2021

Drs. Prevot, Sibille and Colleagues just published their finding in the Journal Cerebral Cortex, about a new molecule reversing brain atrophy and memory dysfunction observed during aging. During aging, our…

April 28, 2020

Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders

Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders http://www.alphacog.ca/wp-content/uploads/2020/04/article-image4.png 1920 800 Etienne Sibille Etienne Sibille http://0.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=g April 28, 2020 June 4, 2020

Cognitive dysfunctions, including impaired attention, learning, memory, planning and problem solving, occur in depressive episodes, often persist during remission, predict relapse, worsen with recurrent episodes, and are not treated by current antidepressants or other medications.

March 28, 2019

Insight into Novel Treatment for Cognitive Dysfunctions across Disorders

Insight into Novel Treatment for Cognitive Dysfunctions across Disorders http://www.alphacog.ca/wp-content/uploads/2020/04/article-image6.png 1920 800 Etienne Sibille Etienne Sibille http://0.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=g March 28, 2019 June 4, 2020

Cognitive dysfunctions, including impaired attention, learning, memory, and problem solving, occur in psychiatric diseases, such as depression, and are a hallmark of aging.

January 23, 2019

Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles

Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles http://www.alphacog.ca/wp-content/uploads/2019/03/article-novel-benbanner.jpg 1920 1000 Etienne Sibille Etienne Sibille http://0.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=g January 23, 2019 June 1, 2020

Altered gamma-aminobutyric acid (GABA) function is consistently reported in psychiatric disorders, normal aging, and neurodegenerative disorders and reduced function of GABA interneurons is associated with both mood and cognitive symptoms.